Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Consensus Price Target from Brokerages

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have received a consensus recommendation of “Buy” from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $9.60.

QNCX has been the topic of a number of research analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Quince Therapeutics in a research note on Wednesday, February 5th. Oppenheimer started coverage on Quince Therapeutics in a research note on Monday. They issued an “outperform” rating and a $10.00 price objective on the stock. Finally, Brookline Capital Management started coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 target price for the company.

Institutional Investors Weigh In On Quince Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Anfield Capital Management LLC bought a new stake in Quince Therapeutics during the fourth quarter worth about $50,000. Virtu Financial LLC purchased a new position in shares of Quince Therapeutics during the 4th quarter valued at about $55,000. Two Sigma Investments LP bought a new stake in Quince Therapeutics in the 4th quarter worth approximately $57,000. Northern Trust Corp lifted its position in Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock worth $94,000 after buying an additional 16,501 shares during the last quarter. Finally, Scharf Investments LLC purchased a new stake in Quince Therapeutics in the fourth quarter worth approximately $170,000. 30.75% of the stock is currently owned by institutional investors.

Quince Therapeutics Stock Up 1.4 %

QNCX stock opened at $1.40 on Tuesday. Quince Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.45. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $61.60 million, a PE ratio of -1.13 and a beta of 0.71. The stock’s 50 day moving average is $1.49 and its 200-day moving average is $1.44.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.